OncLive TV

Dr. Michael Birrer from Massachusetts General Hospital Cancer Center on the Ovarian Cancer Avastin OS Benefit

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

Dr. Sundar Jagannath from the Tisch Cancer Institute Discusses HDAC Inhibitors for Multiple Myeloma

Dr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Isotope Radium-223

Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy

Dr. Freya Schnabel from NYU School of Medicine on Predicting Breast Cancer by Atypia Type

Dr. Harold Harvey from Penn State Hershey Cancer Institute on Aromatase Inhibitor Treatment Duration

Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the NeoACT Sipuleucel-T Study

Dr. Roman Perez-Soler, from Montefiore Medical Center, on Treatment Options for NSCLC

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance

Dr. Paul Hamlin, from Memorial Sloan-Kettering Cancer Center, Discusses Integrating Brentuximab Vedotin

Dr. Barry Rosenbloom, from the Comprehensive Gaucher Treatment Center, on Gaucher Disease Diagnosis Challenges

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer

Dr. Michael Birrer, from Massachusetts General Hospital Cancer Center, Discusses the GOG0218 and ICON7 Trials

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Targeting Dormant Cancer Cells

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway

Dr. Deirdre Cohen, from NYU Medical Oncology Associates, Addresses the Role of the Hedgehog Pathway

Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays

Dr. Kevin Fox, from Abramson Cancer Center, Discusses Genomic Testing in Breast Cancer

Dr. Paul Hamlin from the Memorial Sloan-Kettering Cancer Center on Brentuximab Vedotin Pharmacology

Dr. Neal Weinreb, from University Research Foundation for Lysosomal Storage Diseases, on the Different Roles in a Gaucher Diagnosis

Dr. Ari Zimran, from Shaare Zedek Medical Center, Jerusalem, Discusses Biomarkers in Gaucher Disease